Last reviewed · How we verify
Insulin Fiasp
Insulin Fiasp is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to facilitate glucose uptake and lower blood sugar.
Insulin Fiasp is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to facilitate glucose uptake and lower blood sugar. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Fiasp |
|---|---|
| Also known as | Fiasp® |
| Sponsor | Boston Medical Center |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Fiasp is a mealtime insulin formulation engineered with niacinamide and L-arginine to accelerate insulin absorption and onset of action compared to standard rapid-acting insulins. It mimics the body's natural postprandial insulin secretion more closely, allowing faster glucose control after meals in patients with diabetes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (NA)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor
- Two Way Crossover Closed Loop MPC vs Control IQ (NA)
- Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers (PHASE2, PHASE3)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Fiasp CI brief — competitive landscape report
- Insulin Fiasp updates RSS · CI watch RSS
- Boston Medical Center portfolio CI